BioSpace News Archive

Harbinger Health announced the appointment of Dymeka Harrison as Chief Commercial Officer, Mathew Sargent as Chief Business Officer, and Gisela Paulsen as Chief Operating Officer, positioning the Company for continued growth and platform and product advancement.

The Broad Institute of MIT and Harvard announced a new research alliance with Novo Nordisk aimed at addressing critical unmet clinical needs in diabetes and cardiometabolic diseases.

AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company’s REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.

Verismo Therapeutics today announced that a first patient has been dosed in their STAR-101 clinical trial to study the SynKIR-110 product in individuals with advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

Guardant Health, Inc., a leading precision oncology company, announced that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease test.

PepGen Inc. today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023.

Bionano Genomics, Inc. announced a peer-reviewed publication from researchers at the German Cancer Consortium showing the utility of optical genome mapping and whole-exome sequencing in better understanding the mutational landscape of pediatric B-cell precursor acute lymphoblastic leukemia.

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.

Gracell Biotechnologies Inc. today announced that it will present updated, longer-term results from the ongoing investigator-initiated Phase 1 trial in China evaluating FasTCAR-enabled GC012F in transplant-eligible, high-risk patients with newly diagnosed multiple myeloma (NDMM).

Akebia Therapeutics, Inc. today announced that John Butler , Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023.